select a format

Single User License
USD 3500 INR 227465
Site License
USD 7000 INR 454930
Corporate User License
USD 10500 INR 682395

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146-Pipeline Review, H1 2016

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146-Pipeline Review, H1 2016


  • Products Id :- GMDHC0098TDB
  • |
  • Pages: 67
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Pipeline Review, H1 2016', provides in depth analysis on Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics.

The report provides comprehensive information on the Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)

The report reviews Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects

The report assesses Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Overview 9

Therapeutics Development 10

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Products under Development by Stage of Development 10

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Products under Development by Therapy Area 11

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Products under Development by Indication 12

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Products under Development by Companies 15

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Products under Development by Universities/Institutes 17

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Companies Involved in Therapeutics Development 23

Actinogen Limited 23

Astellas Pharma Inc. 24

AstraZeneca Plc 25

Connexios Life Sciences Pvt. Ltd. 26

F. Hoffmann-La Roche Ltd. 27

Hyundai Pharmaceutical Co., Ltd. 28

Merck & Co., Inc. 29

Pfizer Inc. 30

Poxel SA 31

Sanofi 32

Shanghai Pharmaceutical Co., Ltd. 33

SK Chemicals Co., Ltd. 34

Sumitomo Dainippon Pharma Co., Ltd. 35

Toray Industries, Inc. 36

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Drug Profiles 37

ASP-3662-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

AZD-4017-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CNX-1049-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Drug to Inhibit 11Beta-HSD1 for Hypertension-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Drugs to Inhibit 11beta-HSD1 for Wound Healing-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

DSP-0011-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HIS-388-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HOB-046-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

HSD-621-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

KR-66344-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

NCE-402-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

RG-4929-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

RO-5093151-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SAR-184841-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase for Type 2 Diabetes-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

UE-2343-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Dormant Projects 58

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Discontinued Products 60

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146)-Featured News & Press Releases 61

Mar 22, 2016: XanADu: A New Pivotal Global Clinical Trial to Treat Mild Alzheimer's Disease 61

Sep 29, 2015: Positive Trial Results for Alzheimers Drug Xanamem 62

Aug 11, 2015: Clinical Trial Successfully Completed With Xanamem -AN Alzheimers Drug 62

Jun 11, 2015: Excellent Research Progress With Xanamem-A Promising Alzheimers Drug 63

Apr 13, 2015: EU Patent Granted-Further Extends Xanamem Protection 64

Jun 05, 2013: Enzyme Could Be The Key To Aiding Wound Healing In Diabetic And Elderly People 65

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Figures

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Top 10 Indication, H1 2016 12

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Stage and Mechanism of Actions, H1 2016 20

Number of Products by Stage and Routes of Administration, H1 2016 21

Number of Products by Stage and Molecule Type, H1 2016 22

List of Tables

Number of Products under Development for, H1 2016 10

Number of Products under Development by Therapy Area, H1 2016 11

Number of Products under Development by Indication, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 16

Number of Products under Investigation by Universities/Institutes, H1 2016 17

Products under Investigation by Universities/Institutes, H1 2016 18

Assessment by Monotherapy/Combination Products, H1 2016 19

Number of Products by Stage and Mechanism of Action, H1 2016 20

Number of Products by Stage and Route of Administration, H1 2016 21

Number of Products by Stage and Molecule Type, H1 2016 22

Pipeline by Actinogen Limited, H1 2016 23

Pipeline by Astellas Pharma Inc., H1 2016 24

Pipeline by AstraZeneca Plc, H1 2016 25

Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 26

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 27

Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 28

Pipeline by Merck & Co., Inc., H1 2016 29

Pipeline by Pfizer Inc., H1 2016 30

Pipeline by Poxel SA, H1 2016 31

Pipeline by Sanofi, H1 2016 32

Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016 33

Pipeline by SK Chemicals Co., Ltd., H1 2016 34

Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 35

Pipeline by Toray Industries, Inc., H1 2016 36

Dormant Projects, H1 2016 58

Dormant Projects (Contd..1), H1 2016 59

Discontinued Products, H1 2016 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actinogen Limited

Astellas Pharma Inc.

AstraZeneca Plc

Connexios Life Sciences Pvt. Ltd.

F. Hoffmann-La Roche Ltd.

Hyundai Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Pfizer Inc.

Poxel SA

Sanofi

Shanghai Pharmaceutical Co., Ltd.

SK Chemicals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Toray Industries, Inc.

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Therapeutic Products under Development, Key Players in Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Therapeutics, Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Pipeline Overview, Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Pipeline, Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com